CTOs on the Move

Ironwood Pharmaceuticals

www.ironwoodpharma.com

 
Ironwood is committed to the art and science of making medicines. Patient needs shape our business. They inform our drugmaking process. We rely on patients to help us understand and address those unmet needs. Whether we’re transforming knowledge into medicine or tackling the equally challenging task of delivering that medicine to people around the world, patients inspire us. Shareholders shape our success. Being a shareholder of Ironwood is about more than owning our shares, it's about being an owner of our business. We hope to generate outstanding returns for our shareholders, inspiring their continued support so that we can create more medicines ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Larry Tosi
 Director - Information Technology Operations Profile

Funding

Ironwood Pharmaceuticals raised $150M on 09/26/2016

Similar Companies

Pharmaceutical Services Corp

Pharmaceutical Services Corp is a Pomona, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Oxford Instruments PLC

Oxford Instruments PLC is a Carteret, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cytokinetics

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to increase muscle function and contractility. Cytokinetics’ lead drug candidate is tirasemtiv, a fast skeletal muscle troponin activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the U.S. Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency for the potential treatment of ALS. Cytokinetics retains the right to develop and commercialize tirasemtiv. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure. Cytokinetics is collaborating with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy and chronic obstructive pulmonary disease. Amgen holds an exclusive license worldwide to develop and commercialize omecamtiv mecarbil and Astellas holds an exclusive license worldwide to develop and commercialize CK-2127107. Both licenses are subject to Cytokinetics`​ specified development and commercialization participation rights.

Tarcine

Tarcine is a Thousand Oaks, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CERN Foundation

CERN Foundation is a Dayton, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.